Charts

05 Feb, 2023

News

13 Jan, 2023
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 32.1% to $2.18 during Friday's pre-market session. The market value of their ...
11 Jan, 2023
Gainers Ontrak (NASDAQ:OTRKP) shares moved upwards by 44.1% to $0.92 during Wednesday's regular session. The current volume of 122.0K ...
10 Jan, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up ...
Gainers Sotera Health Company (NASDAQ: SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached ...
Gainers Sotera Health (NASDAQ:SHC) stock moved upwards by 86.9% to $16.15 during Tuesday's regular session. The current volume of 38.4 ...
VYNE Therapeutics Inc(NASDAQ: VYNE) announced that the first vitiligo patienthad been dosedin a Phase 1a/b trial of ...
Gainers Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their ...
Gainers VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
09 Jan, 2023
Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE ...
First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November Topline data expected in 1H 2023 BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first vitiligo patient has been dosed i
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company ...
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
06 Jan, 2023
Gainers Lucira Health (NASDAQ:LHDX) shares rose 29.5% to $0.51 during Friday's after-market session. Lucira Health's trading volume hit ...
05 Jan, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has ...
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock rose 171.1% to $2.48 during Thursday's regular session. As of 12:30 EST, this ...
04 Jan, 2023
Gainers Vyant Bio (NASDAQ:VYNT) shares rose 94.8% to $1.5 during Wednesday's after-market session. Today's trading volume for this ...
12 Dec, 2022
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for o
07 Dec, 2022
Newly issued patent expires in 2040BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that GB Patent No. 2597228 entitled “Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts” has been granted by the United Kingdom’s Intellectual Property Offi
02 Dec, 2022
BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. Panel Prese
18 Nov, 2022
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on D
17 Nov, 2022
Topline proof-of-concept data in vitiligo patients expected in 1H 2023BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for the treatment of vitiligo. VYN201 is a locally administer
10 Nov, 2022
IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of oral, BD2 selective VYN202 program Expanded analysis of FMX114 Phase 2a trial results suggests FMX114 may have the potential to effectively treat patients with moderate-to-severe atopic dermatitis; VYNE currently evaluating development strategy for FMX114 BRIDGEWATER, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE)
22 Sep, 2022
On Thursday, 1076 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with ...
09 Sep, 2022
VYNE Therapeutics (NASDAQ:VYNE) brought in sales totaling $126 thousand during Q2 according to data provided by Benzinga Pro. However, ...
06 Sep, 2022
September 13, 2022BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Manageme
12 Aug, 2022
VYNE Therapeutics (NASDAQ:VYNE) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what ...
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. "We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to co
11 Aug, 2022
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 ...
10 Aug, 2022
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from KarMMa-3, a Phase 3 study ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vir Biotech Shuns FDA ...
VYNE Therapeutics Inc. (NASDAQ: VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for ...
VYNE Therapeutics Inc(NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for ...
BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). Study VY2021-01 did not meet its primary endpoint based on the absolute
19 Jul, 2022
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022. B&T Cell-Mediated Autoimmune Disease Dru
17 Jun, 2022
VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the ...
Top-line Efficacy Results Expected in Approximately 6 to 8 WeeksBRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). FMX114 is VYNE’s proprietary in
18 May, 2022
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be ava
12 May, 2022
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-
10 May, 2022
Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ETBRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNE’s InhiBET™ BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar w
06 May, 2022
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. Virtual Pres
05 May, 2022
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Gainers Intercept Pharmaceuticals (NASDAQ:ICPT) stock increased by 41.2% to $22.86 during Thursday's pre-market ...
28 Apr, 2022
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07 Apr, 2022
VYNE Therapeutics Inc(NASDAQ: VYNE)announced positive efficacyresults from the Phase 1b segment of Phase 1b/2a ...
At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehiclePhase 2a safety and efficacy results expected in the second quarter BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive effi
30 Mar, 2022
VYNE Therapeutics Inc(NASDAQ: VYNE)announced positive preclinical datafrom its VYN201 program in the rheumatoid ...
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibiting inflammation in arthritic joints of mice Data supports potential broad utility of VYN201 as a potent anti-inflammatory molecule delivered across multiple dosage forms BRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) -- VY
18 Mar, 2022
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares increased by 27.8% to $1.77 during Friday's regular session. The ...
According to data from Benzinga Pro, during Q4, VYNE Therapeutics's (NASDAQ:VYNE) reported sales totaled $2.29 million. Despite a 45.64% ...
17 Mar, 2022
13:48
FinancialContent
VYNE Therapeutics (NASDAQ:VYNE) reported its Q4 earnings results on Thursday, March 17, 2022 at 08:00 AM. Here's what ...
07 Mar, 2022
VYNE Therapeutics Inc(NASDAQ: VYNE) hasannounced preclinical datain anex vivoskin model of vitiligo, a ...
19 Jan, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low ...
18 Jan, 2022
10:26
FinancialContent
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently ...
14 Jan, 2022
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical ...
All three major indexes are pacing for their second-straight weekly loss of 2022.
09:43
FinancialContent
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, ...
13 Jan, 2022
In trading on Thursday, information technology services shares were relative laggards, down on the day by about 1.5%. Helping drag down the group were shares of Couchbase, off about 8.3% and shares of Cloudflare down about 7.8% on the day.
Journey Medical Corporation(NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq ...
13 Dec, 2021
10:21
FinancialContent
Gainers SigmaTron International, Inc. (NASDAQ: SGMA) jumped 84.7% to settle at $14.94 on Friday after the company reported Q2 EPS ...
10 Dec, 2021
Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) jumped 43.1% to $2.6909. American Virtual Cloud Technologies ...
09 Nov, 2021

Related Articles